An immune class of HCC characterized by significant immune infiltration, specifically T lymphocyte infiltration with overexpression of PD-1/PD-L1 and CTLA4, is best suited for immune checkpoint inhibitor therapy. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.